Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ohmeda's Revex will launch in late May/early June; color-coded for post-op or opioid overdose reversal.

Executive Summary

OHMEDA REVEX LAUNCH TO OCCUR IN LATE MAY/EARLY JUNE to anesthesiology and emergency medical professionals, the Liberty Corner, N.J.-based subsidiary of the British BOC Group announced April 27. FDA approved NDA 20-459 (nalmefene HCl injection) April 17 for the reversal of opioid drug effects, including postoperative respiratory depression, induced by either natural or synthetic opioids, and for the management of known or suspected opioid overdose ("The Pink Sheet" April 24, In Brief).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel